A Novel Approach for Producing Lentiviruses That Are Limited to a Single Cycle of Infection

Size: px
Start display at page:

Download "A Novel Approach for Producing Lentiviruses That Are Limited to a Single Cycle of Infection"

Transcription

1 JOURNAL OF VIROLOGY, Nov. 2004, p Vol. 78, No X/04/$ DOI: /JVI Copyright 2004, American Society for Microbiology. All Rights Reserved. A Novel Approach for Producing Lentiviruses That Are Limited to a Single Cycle of Infection David T. Evans,* Jennifer E. Bricker, and Ronald C. Desrosiers New England Primate Research Center, Harvard Medical School, Southborough, Massachusetts Received 25 February 2004/Accepted 26 June 2004 We have devised a novel approach for producing simian immunodeficiency virus (SIV) strains and, potentially, human immunodeficiency virus type 1 (HIV-1) strains that are limited to a single cycle of infection. Unlike previous lentiviral vectors, our single-cycle SIV is capable of expressing eight of the nine viral gene products and infected cells release immature virus particles that are unable to complete subsequent rounds of infection. Single-cycle SIV (scsiv) was produced by using a two-plasmid system specifically designed to minimize the possibility of generating replication-competent virus by recombination or nucleotide reversion. One plasmid carried a full-length SIV genome with three nucleotide substitutions in the gag-pol frameshift site to inactivate Pol expression. To ensure inactivation of Pol and to prevent the recovery of wild-type virus by nucleotide reversion, deletions were also introduced into the viral pol gene. In order to provide Gag-Pol in trans, a Gag-Pol-complementing plasmid that included a single nucleotide insertion to permanently place gag and pol in the same reading frame was constructed. We also mutated the frameshift site of this Gag-Pol expression construct so that any recombinants between the two plasmids would remain defective for replication. Cotransfection of both plasmids into 293T cells resulted in the release of Gag-Pol-complemented virus that was capable of one round of infection and one round of viral gene expression but was unable to propagate a spreading infection. The infectivity of scsiv was limited by the amount of Gag-Pol provided in trans and was dependent on the incorporation of a functional integrase. Single-cycle SIV produced by this approach will be useful for addressing questions relating to viral dynamics and viral pathogenesis and for evaluation as an experimental AIDS vaccine in rhesus macaques. Continuous virus replication is a hallmark of lentiviral infections. Indeed, virus replication persists in human immunodeficiency virus (HIV)-infected individuals and simian immunodeficiency virus (SIV)-infected animals in the face of even the most effective antiretroviral drug therapy and immune surveillance (18, 22). This has complicated efforts to experimentally address certain viral dynamic parameters, such as the burst size of virus production, i.e., the ratio of virus produced per infected cell in vivo. Identification of the first cells to become infected during mucosal transmission has also been difficult to determine unambiguously with replication-competent viruses (9, 27, 32). A system for producing SIV strains that are limited to a single cycle of infection would therefore represent a valuable tool for studies of viral dynamics and viral pathogenesis. Lentiviruses that are limited to a single cycle of infection may also represent a promising approach to the development of an AIDS vaccine with nonhuman primate models. We have devised an approach for limiting SIV to a single cycle of infection that takes advantage of a unique combination of mutations in the gag-pol frameshift site that are specifically designed to prevent the generation of wild-type virus by recombination. Gag and Gag-Pol are naturally made from the same mrna transcript at a molar ratio of approximately 20:1 in HIV type 1 (HIV-1)- and SIV-infected cells. This ratio is achieved by ribosomal frameshifting in the region of overlap between the gag and pol reading frames (28). As the precursor to the catalytic subunits of mature virions, Pol is essential for virion maturation and infectivity and its incorporation into assembling virus particles is dependent on its association with Gag (28). The gag-pol frameshift site consists of a conserved seven-nucleotide slippery sequence (UUUUUUA) followed immediately downstream by a region of RNA secondary structure (28). Ribosomal frameshifting physically occurs within the slippery sequence when the trnas for phenylalanine and leucine (codons UUU UUA) slip back one nucleotide ( 1) relative to the gag frame (UUU UUA3UUU UUU) and translation continues in the pol reading frame (10). By introducing into this site mutations that prevent the translation of Pol and by providing Gag-Pol in trans from an expression construct that also contains mutations in the gag-pol frameshift site, we have developed a two-plasmid system for producing Gag-Pol-complemented virus that is limited to a single round of infection. One of the attractive features of this approach is that neither the mutated viral genome nor the Gag-Pol expression construct retains a functional ribosomal frame shift site. Consequently, even if recombination between these two constructs occurs, the resulting virus will remain defective for replication. * Corresponding author. Present address: Department of Pathobiology, Box , School of Public Health and Community Medicine, Washington National Primate Research Center, University of Washington, Seattle, WA Phone: (206) Fax: (206) dte@u.washington.edu. MATERIALS AND METHODS Single-cycle SIV constructs. Mutations were introduced into the gag-pol frameshift site of SIVmac239 to knock out Pol expression by the virus. A 3,989-bp SpeI-to-SacI fragment of gag-pol was cloned into pbluescript II (Stratagene, La Jolla, Calif.), and three nucleotide changes were introduced into the frameshift site with the PCR primers PolFS and FSR (CAGACAGGCGGGC 11715

2 11716 EVANS ET AL. J. VIROL. TTCCTAGGCCTTGGTCCATGGGGAAAGAAGCC and TAGGAAGCCCG CCTGTCTGTCTGGGCATTTGGC, respectively) and a QuickChange site-directed mutagenesis kit (Stratagene). These three nucleotide changes do not change the amino acid coding sequence of gag, and they create a unique AvrII site in the gag-pol frameshift site (26). Deletions of 104, 101, and 105 bp were then introduced into the protease (PR), reverse transcriptase (RT), and integrase (IN) coding regions of pol (nucleotides 2588 to 2691, 2852 to 2951, and 4529 to 4634, respectively (23), with the primer pairs PR/ PR (AGACCA GTAGTCTAGTAGGAGGAATAGGAGGTTTTATTA/TTCCTCCTACTAG ACTACTGGTCTCCTCCAAAGAGAGAA), RT/ RT (TCTCTAAATT TTTAAGAGAAATCTGTGAAAAGATGGAAA/AGATTTCTCTTAAAAAT TTAGAGACATCCCCAGAGCTGT), and IN/ IN (AGACAAGTTCTC TAGTAGACACCTGTGATAAATGTCATC/AGGTGTCTACTAGAGAACT TGTCTAATCCCTTGACTAAC). These mutations were then cloned into a full-length genome with the gene for enhanced green fluorescent protein (EGFP) at the nef locus (2) by using the unique restriction sites SpeI and PacI. An expression construct based on prs102 (24) was created to provide the Gag-Pol polyprotein in trans. In prs102, the cytomegalovirus (CMV) immediate-early promoter drives Gag-Pol expression and inclusion of the Mason-Pfizer monkey virus cis-transport element (CTE) facilitates Rev-independent nuclear export of gag-pol mrna transcripts (24). PCR mutagenesis was performed on a 3,989-bp SpeI-to-SacI fragment of gag-pol in pbluescript II with the primers GPfusF2 and GPfusR2 (GCGGGCTTCCTCAGGCCTTGGTCCATGGGGAA AGAAGCC and CCTGAGGAAGCCCGCCTGTCTGTCTGGGCATTTGGC, respectively). These changes were then cloned back into prs102 to create pgpfusion. By following the same strategy, mutations conferring a combination of three amino acid changes in the active site of integrase (D64Q, D116Q, and E152N) were introduced into pgpfusion to create pgpfusionin. Preparation of virus samples. Virus was prepared by transient transfection of 293T cells with full-length SIV genomes alone or in combination with a Gag-Pol expression construct. Cells were seeded at cells per 100-mm dish the day before transfection, and each dish was transfected with 5 g of each plasmid by calcium phosphate precipitation (ProFection; Promega, Madison, Wis.). Vesicular stomatitis virus glycoprotein (VSV G)-pseudotyped virus was prepared by including 5 g of the VSV G expression construct phdm.g in the transfection mix. The day after transfection, the culture medium (Dulbecco s modified Eagle medium supplemented with 10% fetal bovine serum, L-glutamine, and penicillin) was replaced with a minimal volume (3 ml) of fresh medium. The culture supernatants containing virus particles were harvested 24 h later. The supernatant was either used for infection immediately or concentrated approximately 20-fold by using YM-50 ultrafiltration units (Millipore, Bedford, Mass.) according to the manufacturer s instructions. Because the filtrate is collected by inverse flow in an upper chamber and the virus is never pelleted, ultrafiltration is very gentle and does not significantly reduce virion infectivity. This was demonstrated in a preliminary experiment in which a 25.2-fold concentration, as measured by p27 content (159 to 4,010 ng of p27/ml), translated into a 23.1-fold concentration in single-cycle SIV (scsiv) infectivity ( to IU/ml on CEMx174 cells). Infectivity assays and growth curves. Infectivity assays and growth curves were performed on immortalized human CD4 -T-cell lines, rhesus peripheral blood mononuclear cells (PBMC), and rhesus alveolar macrophages. CD4 -T-cell lines included CEMx174 and T2-SEAP cells. T2-SEAP cells (provided by Welkin Johnson, Harvard Medical School) harbor a Tat-inducible secreted alkaline phosphatase (SEAP) reporter construct enabling SIV infection to be measured by SEAP production in the culture supernatant (20). Rhesus PBMC were isolated from peripheral blood by separation on Ficoll gradients and were activated with phytohemagglutinin (PHA) (1 g/ml) for 2 days before infection. PHAactivated PBMC were maintained in R10 medium (RPMI 1640 medium with 10% fetal bovine serum, L-glutamine, penicillin, and HEPES buffer) supplemented with 20 U of interleukin-2 (IL-2)/ml (provided by Maurice Gately, Hoffman-La Roche, Nutley, N.J.). Macrophages were collected by bronchoalveolar lavage as previously described (21) and were maintained in 48-well plates in R10 medium supplemented with 5% type AB human serum (Sigma). After 2 days of culture, macrophages were infected at a cell density of cells/ well. Virus samples were diluted in R10 medium and used to infect 10 6 cells ( macrophages) in a volume of 100 l for 2 h. Cultures were then expanded to a volume of 2 ml and maintained at 37 C and 5% CO 2. Four days after infection, cells were fixed in 2% paraformaldehyde and analyzed for EGFP expression by using a FACSCalibur flow cytometer (Becton Dickinson). The percentage of EGFP cells in the live cell gate was determined after collecting 100,000 to 200,000 events for each sample. Western blot analysis of virion and cell lysates. SIV was pelleted from the cell culture supernatants at 13,000 rpm for 4 h at 4 C, and virus pellets were resuspended in 2 sodium dodecyl sulfate (SDS) sample buffer. Cell lysates were prepared by harvesting in 2 SDS sample buffer (0.5 ml per 100-mm dish) 2 days after transfection. Samples were boiled for 10 min and separated by SDSpolyacrylamide gel electrophoresis (PAGE). After electrophoresis, the proteins were transferred to polyvinylidene fluoride membranes (Immobilon-P; Millipore) by using a Trans-Blot SD semidry transfer cell (Bio-Rad, Hercules, Calif.). Blots were blocked in 5% milk phosphate-buffered saline Tween and probed with serum pooled from SIV-infected macaques at a 1:200 dilution or a crossreactive monoclonal antibody to HIV-1 p24 capsid (183-H12-5C [4]; obtained from the NIH AIDS Research and Reference Reagent Program) at a 1:400 dilution. Blots were then incubated with horseradish peroxidase (HRP)-conjugated, goat anti-rhesus (1:1000) or anti-mouse immunoglobulin G1 (1:2000) secondary antibodies (Southern Biotechnology, Birmingham, Ala.) and developed with SuperSignal chemiluminescent substrate (Pierce, Rockford, Ill.). Bands were visualized by using a Fujifilm Image Reader LAS-1000 phosphoimager (Fujifilm Photo Film Co., Japan). Sequence analysis of proviral DNA. Genomic DNA was isolated from cryopreserved cell pellets (10 6 cells) by using a QIAamp DNA Blood Mini Kit (QIAGEN, Valencia, Calif.) according to the manufacturer s instructions. A 414-bp region of the SIV genome spanning the gag-pol frameshift site was amplified by PCR from proviral DNA with the forward and reverse primers 621 (AAAGAGGCCCTCGCACCA) and 626 (TCCAAAGAGAGAATTGAGGTG CA), respectively. PCR products obtained after 50 cycles of denaturation (94 C, 30 sec), annealing (50 C, 40 sec), and extension (72 C, 40 sec) were cloned into the pcr4 sequencing vector by TOPO TA cloning (Invitrogen, Carlsbad, Calif.). Multiple independent clones representing the population of proviral DNA sequences were sequenced with the M13 forward and reverse primers provided with the TOPO TA cloning kit. DNA sequencing reactions were performed by using BigDye v3.1 dye terminator mix (ABI, Foster City, Calif.) and analyzed on a 3730XL ABI capillary sequencer at the University of Washington DNA sequencing facility. RESULTS A novel system for producing single-cycle SIV. We introduced nucleotide substitutions into the gag-pol frameshift site of the SIVmac239 genome to create a provirus that was capable of expressing all of the viral gene products except Pol. Three T to C changes (TTTTTTA3CTTCCTA) were introduced into the seven-nucleotide slippery sequence of the gagpol frameshift site. These three nucleotide substitutions inactivated Pol expression by preventing ribosomal frameshifting and were selected in part because they do not change the amino acid sequence of Gag (26). They were incorporated into a full-length SIV genome that also expressed the gene for EGFP from the nef locus (2) to create p239fs EGFP (Fig. 1). Cells infected with this virus therefore express EGFP and can be identified easily by flow cytometry. To complement the inability of p239fs EGFP to express Pol, we created the Gag-Pol expression construct pgpfusion (Fig. 1B). pgpfusion was derived from prs102 (24), in which Gag-Pol expression is driven by the CMV intermediate-early promoter and Rev-independent nuclear export of the gag-pol mrna is facilitated by the Mason-Pfizer monkey virus CTE (3). A single nucleotide insertion was introduced into the gagpol frameshift site of prs102 to permanently place gag and pol in the same reading frame, and the slippery sequence was disrupted with the same three nucleotide changes that were made in the viral genome (TTTTTTA3CTTCCTCA). Thus, pgpfusion expresses Gag-Pol, but not Gag. Since pgpfusion lacks the major packaging sequences ( ) upstream of gag, the potential for copackaging and RNA-RNA recombination with the viral genome was greatly reduced. Together, p239fs EGFP and pgpfusion constitute a two-

3 VOL. 78, 2004 SINGLE-CYCLE SIV FIG. 1. Plasmid DNA constructs for producing single-cycle SIV. (A) Three nucleotide substitutions were introduced into the gag-pol frameshift site of a full-length SIVmac239 clone carrying the gene for EGFP at the nef locus to create p239fs EGFP. Derivatives of p239fs EGFP with different combinations of deletions in the integrase ( IN) and protease ( PR) coding regions of pol (p239fs INEGFP and p239fs PR INEGFP) and a deletion in vif (pfs PR IN vifegfp) were also created. (B) Two different expression constructs, pgpfusion and pgpfusionin, were created to provide Gag-Pol in trans. These constructs were derived from the SIV Gag-Pol expression construct prs102, which uses the CMV promoter to drive Gag-Pol expression and the MPMV CTE element to facilitate the nuclear export of gag-pol mrna transcripts in the absence of Rev (24). To create pgpfusion, four nucleotide changes, including a single nucleotide insertion to place gag and pol in the same reading frame, were introduced into the gag-pol frameshift site of prs102. This construct was subsequently modified by the introduction of mutations that confer three amino acid substitutions in the active site of integrase (D64Q, D116Q, and E152N) to create pgpfusionin. plasmid system for producing Gag-Pol-complemented virus by transient transfection. The virus produced by cotransfection of these two plasmid DNA constructs should package a viral genome deficient for Pol expression and therefore be limited to one round of proteolytic maturation, reverse transcription, and proviral integration. The principal advantage of this approach is that it is no longer possible to generate replicationcompetent virus simply by recombination between the two plasmids, since neither construct retains a functional gag-pol frameshift site. Gag-Pol-complemented frameshift site mutants are limited to a single cycle of infection. The phenotype of Gag-Pol-complemented SIV with mutations in the frameshift site (FS scsiv-egfp) was initially characterized by infection of human CD4 -T-cell lines. The culture supernatants were collected from 293T cells cotransfected with p239fs EGFP and pgpfusion and used to infect CEMx174 and T2-SEAP cells, which harbor a Tat-inducible SEAP reporter construct (20). Virus infectivity was linearly dose dependent over a 3-log range as measured by the number of EGFP cells and by SEAP production 4 days after infection (Fig. 2A). The course of FS scsiv-egfp infection was then compared to the frameshift site mutant produced in the absence of pgpfusion (FS SIV- EGFP) and to wild-type SIV (Wt SIV-EGFP) (Fig. 2B). In cultures infected with the Gag-Pol-complemented virus, the number of EGFP cells reached peak levels 3 to 7 days postinfection and steadily declined over the following 3 weeks (Fig. 2B). In contrast, no EGFP cells were observed in cultures infected with FS SIV-EGFP produced in the absence of Gag- Pol-complementation consistent with the requirement for Gag-Pol incorporation in trans to produce infectious virus particles (Fig. 2B). As expected, wild-type virus spread rapidly through infected cultures, resulting in 90% EGFP cells by day 11 (Fig. 2B). Recent evidence suggests that some viral protein expression can occur from unintegrated proviral DNA (31). We therefore determined whether a functional integrase was necessary for EGFP expression in cells infected with our Gag-Pol-complemented frameshift site mutant. Mutations conferring amino acid changes in active site residues of integrase (D64Q, D116Q, and E152N) were introduced into pgpfusion to create pgpfusionin (Fig. 1B). Each of these three amino acid changes alone is sufficient to eliminate proviral integration without adversely affecting virion assembly or morphology (5, 16, 29). Thus, the cotransfection of p239fs EGFP and pgpfusionin should produce virus containing functional protease and reverse transcriptase but not integrase [FS scsiv(in )- EGFP]. As with control cultures infected with virus produced in the absence of Gag-Pol complementation, no EGFP cells were observed in cultures infected with FS scsiv(in )- EGFP despite the use of a high dose of virus inoculum (250 ng of p27) (Fig. 2C). Indeed, the levels of EGFP expression for FS scsiv-egfp were such that 100-fold less EGFP expression by FS scsiv(in )-EGFP infected cells would have been detected readily. Therefore, a functional integrase and presumably integration of proviral DNA appears to be essential for infection by our Gag-Pol-complemented SIV frameshift site mutant. Deletions in pol and vif were introduced to prevent the recovery of replication-competent virus by nucleotide reversion. Since p239fs EGFP only differs from a replication-competent SIV genome by three nucleotides, nucleotide reversions or compensatory changes in the gag-pol frameshift site could conceivably lead to the generation of replication-competent viruses. We therefore introduced additional deletions into the viral genome to further guard against the emergence of replication-competent viruses. Deletions of approximately 100 bp were made in the PR, RT, and IN coding regions of pol ( PR , RT , and IN , respectively) (23) in combination with the three nucleotide substitutions in the gag-pol frameshift site to create p239fs PREGFP, p239fs RTEGFP, and p239fs INEGFP. These deletions

4 11718 EVANS ET AL. J. VIROL. FIG. 2. Properties of single-cycle SIV infection in human CD4 -T-cell lines. (A) FS scsiv-egfp was produced by cotransfection of p239fs EGFP and pgpfusion into 293T cells. T2-SEAP cells containing a Tat-inducible SEAP reporter construct (20) were infected with 2.5, 25, and 250 ng of p27 equivalents of FS scsiv-egfp. Four days after infection, infectivity was measured by determining the percentage of EGFP cells by flow cytometry and SEAP production in the culture supernatants. (B) CEMx174 cells were infected with FS scsiv-egfp, the frameshift site mutant produced in the absence of Gag-Pol-complementation (FS SIV-EGFP) and the wild-type (Wt SIV-EGFP). The course of infection by each virus was monitored over a 1-month period by determining the percentages of EGFP cells by flow cytometry. (C) CEMx174 cells were infected with FS scsiv-egfp, an integrase-deficient scsiv [FS scsiv(in )-EGFP], and FS SIV-EGFP at a dose of 250 ng of SIV p27 equivalents for each virus. FS scsiv(in )-EGFP was produced by cotransfection of 293T cells with p239fs EGFP and pgpfusionin. Since pgpfusionin expresses Gag-Pol with three amino acid changes in the active site of integrase (D64Q, D116Q, and E152N), FS scsiv(in )- EGFP particles incorporate a Gag-Pol polyprotein with a functionally inactive integrase and are unable to complete proviral integration. The progress of infection by each of these viruses was monitored by flow cytometry. TABLE 1. Infectivity titers of single-cycle SIV strains scsiv strain a Infectivity titer b IU/ng IU/ml (10 6 ) FS IN scsiv-egfp FS PR IN scsiv-egfp FS PR IN vif scsiv-egfp a Single-cycle SIV stocks were prepared by transient transfection in 293T cells and concentrated approximately 20-fold by ultrafiltration in YM-50 units (Millipore) with a 50-kDa pore size. CEMx174 cells (10 6 ) were infected in duplicate with 100 ng of p27 equivalents of each scsiv strain as determined by an SIV p27 antigen capture ELISA (Coulter, Miami, Fla.). b Infectivity titers were measured 4 days after infection and are expressed as the numbers of EGFP cells (IU) per nanogram of p27 and per milliliter of virus inoculum. Ranges indicate standard deviations from the means for duplicate wells. did not reduce the infectivity of scsiv, since Pol expression by the viral genome was silenced by the disruption of the gag-pol frameshift site (data not shown). However, the deletions decreased the theoretical likelihood that these mutants would regain the capacity to replicate, since both a recombination event in pol and nucleotide reversions in the gag-pol frameshift site would be necessary to restore a replication-competent genome. The original frameshift site mutant was then combined with deletions in both the PR and IN coding regions to create p239fs PR INEGFP so that a double recombination event or a recombination over a large region would be required to restore the complete pol reading frame. As expected, the infectivity of this double-deletion mutant (FS PR IN scsiv- EGFP) did not differ significantly from that of a mutant with a single deletion (FS IN scsiv-egfp) (Table 1). The infectivities of these scsiv strains also compared favorably to the infectivity of a stock of wild-type SIVmac239 (540 50% tissue culture infectious dose/ng), which was determined previously with the same cells by limiting dilution. As an additional safeguard to minimize the chances of recovering replication-competent viruses, the mutations were combined with a deletion of 234 nucleotides in vif (7) to create p239fs PR IN vifegfp (Fig. 1). Vif is required to overcome a cellular block to infectivity that is imposed by the virus producer cell (6, 25, 30), and while vif deletion mutants produced from most cells are not infectious, vif-deleted viruses produced from certain cell types, such as 293T cells, retain full infectivity. Therefore, under certain circumstances, vif deletion mutants may behave like single-cycle viruses and may be used to back up scsiv mutations in pol. In CEMx174 cells infected with FS PR IN vif scsiv-egfp, the incorporation of the vif deletion did not reduce virus infectivity (Table 1). Since the complete vif gene is not present in the Gag-Pol-complementing construct, this deletion cannot be restored by recombination. Virus particles released from scsiv-infected cells are unable to complete proteolytic maturation. Since the nucleotide substitutions in the gag-pol frameshift site were designed to knock out Pol expression from the viral genome, virions released from scsiv-infected cells should be unable to complete proteolytic maturation due to the absence of the viral protease. To confirm this prediction, we infected 221 cells, an IL-2-dependent rhesus macaque CD4 -T-cell line (1), with scsiv and examined the protein profile of virus released from these cells in comparison to samples of wild-type SIV and the scsiv inoculum (Fig. 3). Two different strains of scsiv were used for infection. One contained only the three original nucleotide changes in the frameshift site (FS scsiv-egfp), while the other included additional backup deletions in the PR and IN coding regions of pol (FS PR IN scsiv-egfp). Due to nearly complete proteolytic processing, only the p55gag cleavage products p27 capsid and p17 matrix were visible for wildtype SIV (Fig. 3, lanes 1 and 4). Similarly, p27 and p17 were the predominant forms of Gag in both scsiv inoculum samples, although a weaker p55 band that was also detected likely reflects suboptimal Gag-Pol incorporation and incomplete proteolytic processing (Fig. 3, lanes 2 and 5). In contrast, virus

5 VOL. 78, 2004 SINGLE-CYCLE SIV FIG. 3. Virus released from scsiv-infected cells is unable to complete proteolytic maturation. The protein profile of scsiv was compared to the protein profile of progeny virus released from scsivinfected cells. A rhesus T-cell line (221) (1) was infected with FS scsiv-egfp and FS PR IN scsiv-egfp. Four days after infection, the virus released from these cells was harvested and analyzed alongside wild-type SIV and a sample of each scsiv inoculum: wildtype SIV-EGFP (lanes 1 and 4), FS scsiv-egfp (lane 2, inoculum; lane 3, progeny virus), and FS PR IN scsiv-egfp (lane 5, inoculum; lane 6, progeny virus). Viral proteins were separated on a 10% polyacrylamide gel and analyzed by Western blotting with serum pooled from SIV-infected macaques (1:200) and a goat anti-rhesus HRP-conjugated secondary antibody (1:1000). Bands were visualized after development in SuperSignal chemiluminescence substrate (Pierce) by using an Image Reader LAS-1000 phosphoimager (Fujifilm). released from scsiv-infected cells contained predominantly or exclusively unprocessed p55gag (Fig. 3, lanes 3 and 6). Thus, the protein profile of the virus produced by scsiv-infected cells resembles that of immature virions that are unable to complete proteolytic maturation. A faint p27 band was also observed in virus collected from cells infected with FS scsiv- EGFP containing only the frameshift site changes (Fig. 3, lane 3), but it was not detected in virus produced by cells infected with FS PR IN scsiv-egfp carrying additional deletions in protease and integrase (Fig. 3, lane 6). This result suggests that the frameshift site mutations are leaky and may permit a low level of Pol translation. Deletions in pol are necessary to prevent virus spread at high multiplicities of infection. While the frameshift site mutations alone were sufficient to prevent virus spread when the frequency of scsiv infection was limited to 5% (Fig. 2), the finding that these changes may not completely eliminate Pol translation raises the possibility for breakthrough spreading infection at higher multiplicities of infection. We therefore tested for the presence of virus replication under more rigorous assay conditions designed to maximize the numbers of scsiv-infected cells. CEMx174 cells were infected with concentrated, VSV G- pseudotyped stocks of FS scsiv-egfp and FS PR IN scsiv-egfp. By enabling CD4- and chemokine receptor-independent cell entry, VSV G pseudotyping substantially increased the infectivity of each of these strains, resulting in about 90% infection by day 4 (Fig. 4A). On day 4, the supernatant was collected from the cultures and passed directly to fresh CEMx174 cells. These cultures were then monitored for spreading infection over a period of 3 to 4 weeks. The supernatant from cells infected with FS scsiv-egfp resulted in detectable spreading infection by 11 days posttransfer (Fig. 4A). However, there was no evidence of spreading infection after transfer of the supernatant from cells infected with FS PR IN scsiv-egfp (Fig. 4A). This finding was further confirmed by the inability to detect SIV p27 in the supernatant from FS PR IN scsiv-egfp cultures by antigen capture enzyme-linked immunosorbent assay (ELISA) on day 25 posttransfer. Thus, at high multiplicities of infection, additional back-up deletions in pol do appear to be necessary to prevent spreading infection. To investigate the mechanism of spreading infection in the FS scsiv-egfp culture, we sequenced a region of proviral DNA spanning the p2 coding region of gag through the PR coding region of pol. Genomic DNA was isolated from cells collected on days 16 and 26, and a 414-bp region encompassing the gag-pol frameshift site was PCR amplified from proviral DNA, cloned, and sequenced. Surprisingly, all of the clones retained the original three T3C changes in the slippery sequence, suggesting that spreading infection was not the result of nucleotide reversion. Furthermore, most of the clones represented the predicted sequence for the FS scsiv-egfp inoculum. The only new mutation that was consistently observed at each time point was a 167-bp deletion (nucleotides 2177 to 2343) (23) beginning in the p2 coding region of gag and ending seven nucleotides upstream of the mutated slippery sequence (Fig. 4B). This unusual deletion was present in 3 of 18 clones at day 16 and in 1 of 15 clones at day 26. Interestingly, the deletion eliminated the entire nucleocapsid (NC) coding region of gag and placed the gag and pol genes in the same reading frame. Integrated proviruses containing this mutation are therefore predicted to express a mutated form of Gag-Pol lacking amino acid sequences for NC. These proviruses should also be unable to express p6 residues of Gag, since the p6 coding region downstream of the deletion is out of the frame. Virions produced from this mutant should therefore be defective for replication due to an inability to express NC and p6, which are required for the packaging of viral RNA and the release of virions from infected cells, respectively. Thus, sequence analysis of the FS scsiv-egfp culture did not reveal any mutations in proviral DNA predicted to produce replication-competent virus. However, it is conceivable that the observed spreading infection may be due to two defective viral genomes complementing each other. In this case, the 167-bp deletion mutant may provide Gag-Pol to complement the original FS scsiv genome, allowing both viruses to spread in tandem. This intriguing possibility is supported by the dependence of spread on a high multiplicity of infection and the maintenance of each provirus at early and late stages of infection. The infectivity of single-cycle SIV is limited by Gag-Pol incorporation in trans. The infectivity of scsiv was compared to the infectivity of wild-type SIV by normalizing the number of infected cells to the amount of SIV p27 present in the inoculum. CEMx174 cells were infected with FS scsiv-egfp prepared by transfection of 293T cells with pgpfusion and p239fs EGFP at five different plasmid ratios. Cells were analyzed for EGFP expression on days 2 and 3 postinfection, when the majority of the EGFP cells in the wild-type SIV

6 11720 EVANS ET AL. J. VIROL. Downloaded from FIG. 4. At high multiplicity of infection with VSV G-pseudotyped virus, spreading infection was observed after the supernatant transfer from FS scsiv-egfp but not from FS PR IN scsiv-egfp-infected cells. (A) One million CEMx174 cells were infected with 100 ng of p27 equivalents of concentrated, VSV G-pseudotyped FS scsiv-egfp and FS PR IN scsiv-egfp. Infections were performed in a volume of 100 l for 2 h, which was then expanded to 2 ml. On day 4 postinfection, 1 ml of the supernatant was passed to one million fresh CEMx174 cells for a total culture volume of 2 ml and these cells were monitored for 3 to 4 weeks. Cells were fixed and analyzed for EGFP expression on day 4 postinfection (PI) and on days 11 and 21 posttransfer (PT). The percentage of infected, EGFP-positive cells is indicated at each time point. (B) An unusual 167-bp deletion was present in sequences amplified from proviral DNA of the FS scsiv-egfp culture. Genomic DNA was prepared from cryopreserved cell pellets collected on days 16 and 26 after the supernatant transfer. A 414-bp region of the SIV genome spanning the gag-pol frameshift site was PCR amplified from proviral DNA and cloned into the TOPO TA sequencing vector pcr4. An analysis of multiple independent clones revealed the presence of two predominant proviral sequences within this region. FS represents the proviral sequence of the FS scsiv-egfp inoculum that was present in the majority of clones at each time point. 167 contains a unique 167-bp deletion that was identified in 3 of 18 clones on day 16 and 1 of 15 clones on day 26. The predicted amino acid sequences for Gag and Pol and the proteolytic cleavages sites for p2/nc, NC/p6, and transframe (TF)/PR are indicated by. on June 30, 2018 by guest infected cultures represented the first round of infection. As the amount of pgpfusion relative to that of p239fs EGFP was reduced, the infectivity of the virus declined, revealing a dose-dependent relationship between scsiv infectivity and the ratio of the two constructs used to produce the virus (Fig. 5A). Contrary to our initial expectations, the maximal scsiv infectivity was achieved at the highest ratio of pgpfusion to p239fs EGFP (Fig. 5A). Since the ratio of Gag-Pol to Gag in cells infected with wild-type virus is approximately 1:20, we had predicted that only 1/20 the amount of Gag-Pol expression relative to Gag would be needed to assemble fully infectious virus particles. Thus, the infectivity of scsiv appeared to be limited by the incorporation of Gag-Pol in trans. We therefore analyzed the profile of viral proteins in scsiv prepared at decreasing ratios of pgpfusion to p239fs EGFP. Virus samples were separated by SDS-PAGE and analyzed on a Western blot with serum pooled from SIV-infected animals. Similar to the results for the wild-type virus, the unprocessed p55 Gag band was not visible for scsiv produced at the highest ratios of pgpfusion to p239fs EGFP (Fig. 5B). However, as the ratio of pgpfusion to p239fs EGFP was decreased, the p55 Gag band became visible and increased in intensity (Fig. 5B). Due to the intensity of p55 Gag staining at the lower plasmid ratios, only the most abundant viral antigens (gp120, p55, p27, and p17) were visible. We were therefore unable to detect bands corresponding to the Pol cleavage products RT and IN in wild-type or scsiv virions. Since an antigen capture assay that detects p27 CA, but not unprocessed p55 Gag, was

7 VOL. 78, 2004 SINGLE-CYCLE SIV FIG. 5. The infectivity of scsiv is dependent on Gag-Pol incorporation in trans. (A) CEMx174 cells were infected with FS scsiv- EGFP produced at five different plasmid ratios, and the numbers of EGFP cells were determined by flow cytometry on days 2 and 3 postinfection. FS scsiv-egfp was produced by cotransfection of 293T cells with pgpfusion and p239fs EGFP at ratios of 20:1 (20:1 g), 10:1 (10:1 g), 5:1 (10:2 g), 1:1 (5:5 g) and 1:5 (2:10 g). Control cultures were infected with wild-type SIV-EGFP and FS SIV-EGFP produced in the absence of pgpfusion. The infectivities of each sample were compared by normalizing the numbers of EGFP cells to the amount of SIV p27 present in the inoculum. (B) Virion protein profiles for FS scsiv-egfp samples produced at decreasing ratios of pgpfusion to p239fs EGFP were compared by Western blot analysis. FS scsiv-egfp was produced by cotransfection of 293T cells with pgpfusion and p239fs EGFP at ratios of 10:1 (10:1 g), 5:1 (5:1 g), 1:1 (5:5 g), 1:5 (1:5 g), 1:10 (0.5:5 g), 1:50 (0.1:5 g), and 1:100 (0.05:5 g). Wt SIV-EGFP and FS SIV-EGFP were produced by transfection of p239egfp and p239fs EGFP, respectively (5 g each). Virus was pelleted from the culture supernatants and resuspended in SDS-PAGE sample buffer. Five nanograms of SIV p27 equivalents of each viral lysate was separated on an SDS-10% polyacrylamide gel and transferred to a nylon membrane. The blot was probed with pooled serum from SIV-infected macaques (1:200) and goat anti-rhesus HRP-conjugated secondary antibody (1:1000) and was developed by using SuperSignal (Pierce) chemiluminescence substrate. Bands were visualized following a 30-s exposure by using a Fujifilm Image Reader LAS-1000 phosphoimager. used to standardize the amount of virus loaded per lane, the intensity of the gp120 Env band also increased as increasing amounts of immature virus particles were loaded to achieve a constant loading of p27 (Fig. 5B). These results confirm that Gag-Pol incorporation into scsiv particles is reduced at lower transfection ratios of pgpfusion to p239fs EGFP and corroborate the dose dependence of scsiv infectivity on the ratio of these two plasmids. The phenomena of cotranslational packaging and assembly may account for the need to transfect excess pgpfusion to achieve wild-type levels of Gag-Pol in virions. According to this model, nascent Gag and Gag-Pol polyproteins preferentially associate with full-length genomic RNA and each other during or immediately after protein translation (8, 13). As a consequence, Gag-Pol expressed in trans from pgpfusion may be at a competitive disadvantage relative to Gag expressed from the FS viral genome for incorporation into virus particles. Alternatively, the need to provide excess pgpfusion may simply reflect inefficient protein expression from this construct. To differentiate between these two possibilities, we compared the levels of Gag-Pol expression in cells transfected with pgpfusion alone or together with the scsiv genomic constructs p239fs EGFP and p239fs PR INEGFP to cells transfected with the wild-type proviral construct p239egfp (Fig. 6A). We also compared the efficiency of proteolytic processing of Gag for virions released from these cells (Fig. 6B). Western blots of 293T cell lysates and virus pellets were probed with a monoclonal antibody to the HIV-1 capsid protein that cross-reacts with SIV p27 and its polyprotein precursors (4). A 160-kDa band corresponding to Gag-Pol was readily detectable in cells transfected with pgpfusion alone (Fig. 6A, lane 2) and in cells cotransfected at 10:1 and 1:1 ratios with a constant mass of pgpfusion plus either p239fs EGFP (lanes 3 and 4) or p239fs PR INEGFP (lanes 6 and 7). In contrast, Gag-Pol was not observed in cells transfected with wild-type proviral DNA (Fig. 6A, lane 1) due to the naturally low levels of protein expression afforded by frameshift suppression. The overabundance of Gag-Pol in cells transfected with pgpfusion relative to cells transfected with wild-type proviral DNA suggests that the efficiency of protein expression from pgpfusion is not a limiting factor in the proteolytic maturation of scsiv. An overabundance of Gag-Pol in cells did not translate into excess unprocessed Gag-Pol in virus particles. In contrast to the results with cell lysates, the 160-kDa Gag-Pol band was not detectable in any of the virus samples regardless of the plasmid ratio used for transfection (Fig. 6B). While the proteolytic processing of p55gag in wild-type virions (Fig. 6B, lane 1) and in scsiv produced at 10:1 ratios of pgpfusion to p239fs EGFP and p239fs PR INEGFP (lanes 3 and 6) was nearly complete, p55gag cleavage remained incomplete at plasmid ratios of 1:1 (Fig. 6B, lanes 4 and 7). These observations further suggest that Gag-Pol incorporation into scsiv is less efficient than in wild-type virus and support a model in which RNA packaging and virus assembly may occur by cotranslational mechanisms. Single-cycle SIV infection of primary macrophages and T cells. Although SIV infects both CD4 T cells and macrophages in vivo, productive infection by SIVmac239 is primarily restricted to T cells. To generate a strain of scsiv that was also

8 11722 EVANS ET AL. J. VIROL. FIG. 6. Comparison of Gag and Gag-Pol in producer cells and virions for wild-type and single-cycle SIV. Whole cell lysates (A) and virus pellets (B) were prepared from 293T cells and the culture supernatants 2 days after transfection with wild-type and single-cycle SIV plasmid constructs. Cells were transfected individually with the wildtype proviral construct p239egfp (lane 1), the Gag-Pol-complementing construct pgpfusion (lane 2), the scsiv genomic constructs p239fs EGFP (lane 5), and p239fs PR INEGFP (lane 8). Additional cells were cotransfected with pgpfusion plus p239fs EGFP (lanes 3 and 4) and pgpfusion plus p239fs PR INEGFP (lanes 6 and 7) at ratios of 10:1 and 1:1, respectively. Individual transfections were performed with a total of 6 g of each plasmid, and cotransfections were performed with a constant mass of pgpfusion (6 g) together with 0.6 g (10:1) or 6 g (1:1) of each scsiv genomic construct. Samples were separated on SDS-8% polyacrylamide gels and transferred to nitrocellulose membranes. Western blots were probed with a cross-reactive monoclonal antibody to HIV-1 p24 (183-H12-5C; 1:400) (4) and an HRP-conjugated goat anti-mouse secondary antibody (1:2000). After saturation with SuperSignal chemiluminescence substrate (Pierce), bands were visualized following exposure times of 1 min for cell lysates (A) and 5 min for virus pellets (B). FIG. 7. Infection of primary macrophages and T cells with singlecycle SIV. Primary alveolar macrophages (A) and PHA-activated PBMC (B) from two different rhesus macaques (Mm and Mm174-91) were infected with scsiv strains (FS IN) bearing T-celltropic (239) and macrophage-tropic (316) envelope glycoproteins. Infections were monitored by measuring the percentages of EGFP cells in each culture by flow cytometry. capable of infecting macrophages, a fragment of the macrophage-tropic SIVmac316 env gene (21), encoding six amino acid differences in gp120 and one amino acid difference in gp41, was exchanged with SIVmac239 env sequences in p239fs INEGFP. Concentrated stocks of FS IN scsivmac239 and FS IN scsivmac316 were prepared and used to infect primary alveolar macrophages and PHA-activated PBMC from two different rhesus macaque donors. Similar to the results with scsiv infection of CEMx174 cells, there was an initial increase in the number of infected EGFP cells during the first few days after infection followed by a gradual decline of this population over the following weeks of culture (Fig. 7). Both scsivmac239 and scsivmac316 were more infectious for PHA-activated PBMC than for macrophages (Fig. 7), and infectivity titers for activated PBMC ranged from 1,196 to 2,880 IU/ng and from 992 to 2,507 IU/ng, respectively (Table 2). However, the infectivity of scsivmac316 for macrophages was more than 10-fold higher than that of scsivmac239 (Table 2). These scsiv variants therefore recapitulated the cellular tropism of their parental strains and exhibited a phenotype consistent with a single cycle of infection in primary cell types. DISCUSSION We have devised a novel two-plasmid system for producing strains of SIV that are limited to a single cycle of infection. Three nucleotide substitutions were introduced into the heptanucleotide slippery sequence of the SIV gag-pol frameshift site to knock out Pol expression by the virus. To provide Gag- Pol in trans, a Gag-Pol expression construct was created with a single nucleotide insertion to permanently place gag and pol in the same reading frame. Nucleotide changes were also introduced into the frameshift site of this construct so that neither the viral genome nor the complementing construct retained a functional gag-pol frameshift site, thereby preventing the recovery of wild-type virus by recombination alone. To prevent the recovery of replication-competent virus as a result of reversion of changes in the frameshift site, additional back-up deletions were introduced into the pol and vif genes of the viral

9 VOL. 78, 2004 SINGLE-CYCLE SIV TABLE 2. Relative infectivities of scsivmac239 and scsivmac316 for PBMC and macrophages Cell type and scsiv strain c Donor IU/ng Infectivity titer d IU/ml (10 6 ) PBMC a scsivmac239 Mm Mm scsivmac316 Mm Mm Macrophage b scsivmac239 Mm Mm scsivmac316 Mm Mm a Two days after isolation and stimulation with PHA (1 g/ml), activated PBMC (10 6 ) were infected with 75 ng of p27 equivalents of scsivmac239 and FS IN scsivmac316. b Macrophages were collected by bronchoalveolar lavage, and adherent cells ( ) were infected with 37.5 ng of p27 equivalents of scsivmac239 and scsivmac316 after 2 days in culture. c Single-cycle SIV strains expressing EGFP from the nef locus were prepared by cotransfection of 293T cells with pgpfusion and either p239fs INEGFP or p316fs INEGFP. Virus stocks were concentrated approximately 20-fold by ultrafiltration. d Infectivity titers are expressed as the numbers of infected EGFP cells per nanogram of p27 and per milliliter of concentrated supernatant. The number of EGFP cells was determined on day 4 postinfection for PBMC and on day 5 postinfection for macrophages. genome. Together, these constructs constitute a two-plasmid system for producing scsiv by transient transfection that is specifically designed to minimize the chances of generating replication-competent virus by recombination or nucleotide reversion. In immortalized and primary cells that are permissive for wild-type SIV replication, the numbers of scsiv-infected cells peaked during the initial days after exposure to the virus and then steadily declined as the cultures were maintained over a 3- to 4-week period. Viral protein expression in scsiv-infected cells was dependent on a functional integrase and, presumably, on proviral integration, since EGFP expression became undetectable when a Gag-Pol-complementing construct with mutations in the active site of integrase was used to produce the virus. The initial increase in the numbers of scsiv-infected cells reflects, at least in part, the time required for virus receptor binding, cell entry, reverse transcription, proviral integration, the expression of Tat, and the accumulation of EGFP to detectable levels. Conversely, the relatively slow decline of the scsiv-infected cell population is likely due to the death of infected cells and/or a growth disadvantage of cells harboring integrated proviruses due to cytopathic effects associated with viral protein expression. Potential factors selecting against infected cells include Env-induced cell killing through membrane fusion (17) and cell cycle arrest by the Vpr protein (11). The silencing of proviral gene expression and the loss of EGFP expression as a result of LTR promoter methylation may also have contributed to the apparent decline in the numbers of scsiv-infected cells in these experiments. In either case, the course of infection by scsiv in otherwise permissive cell types is consistent with the phenotype of a virus that is limited to a single round of integration and viral protein expression. We have not detected any evidence of spreading infection in cultures infected with scsiv at low multiplicities of infection or in cultures infected at higher infectious doses with scsiv strains containing additional back-up deletions in pol. Additionally, we have now inoculated macaques intravenously with multiple concentrated doses ( virus particles) of an scsiv strain carrying a single back-up deletion in the IN coding region of pol and have not observed spreading infection in vivo (D. T. Evans et al., unpublished data). This finding suggests that the combination of nucleotide changes in the gag-pol frameshift site with even a single downstream deletion in pol is sufficient to prevent virus replication at high doses of inoculation in animals perhaps the most rigorous test for the recovery of replication-competent virus thus far. Nevertheless, spreading infection was observed following the supernatant transfer from cells infected at a high infectious dose with VSV G-pseudotyped scsiv containing the initial nucleotide substitutions in the gag-pol frameshift site without additional back-up mutations. Sequence analysis of proviral DNA from this culture did not reveal any evidence of nucleotide reversion of the frameshift site mutations. However, an unusual 167-bp deletion was observed in approximately 12% of the clones that eliminated the NC coding region of gag and placed downstream pol sequences in the same reading frame. This provirus is unlikely to produce replication-competent virus, due to an inability to express both NC and p6 sequences of Gag. Thus, we did not identify any proviral mutations expected to produce replication-competent virus. However, since integrated proviruses containing this deletion are predicted to express a mutated form of Gag-Pol, this genome could in principle complement the original frameshift site mutant to enable the tandem spread of both replication-defective genomes through the culture. This possibility is supported by the dependence of spread on a high multiplicity of infection and the observation that the frequency of the deletion mutant did not increase at late stages of infection. Kuate et al. recently described an alternative approach for producing single-cycle SIV based on nucleotide substitutions in the primer-binding site (PBS) and complementation with an artificial trna (15). To further attenuate the virus, additional deletions were introduced into the vif, vpx, vpr, and nef genes. With the possible exception of the deletion in vif, however, none of these back-up deletions are expected to prevent virus replication. Therefore, replication-competent viruses may be recovered by point mutation in the PBS alone, in contrast to our system. Our approaches also differ with respect to the nature of the block to virus replication. After the first round of infection, virus produced by the approach described by Kuate et al. is blocked at the initiation of reverse transcription due to the absence of a cellular trna complementary to the mutated PBS sequence. Since we inactivated Pol expression by mutating the gag-pol frameshift site, virus released from cells infected with our scsiv encounters an earlier block at the stage of proteolytic maturation. As a result, our progeny virions have protein profiles that resemble those of immature virus particles. Both approaches retain the expression of similar percentages of overall SIV coding sequences, although the numbers of functional genes retained are quite different. With the exception of a single construct with a deletion in vif, we limited our inactivating mutations to the viral pol gene. We elected to

VIROLOGY. Engineering Viral Genomes: Retrovirus Vectors

VIROLOGY. Engineering Viral Genomes: Retrovirus Vectors VIROLOGY Engineering Viral Genomes: Retrovirus Vectors Viral vectors Retrovirus replicative cycle Most mammalian retroviruses use trna PRO, trna Lys3, trna Lys1,2 The partially unfolded trna is annealed

More information

Fayth K. Yoshimura, Ph.D. September 7, of 7 HIV - BASIC PROPERTIES

Fayth K. Yoshimura, Ph.D. September 7, of 7 HIV - BASIC PROPERTIES 1 of 7 I. Viral Origin. A. Retrovirus - animal lentiviruses. HIV - BASIC PROPERTIES 1. HIV is a member of the Retrovirus family and more specifically it is a member of the Lentivirus genus of this family.

More information

Supplemental Materials and Methods Plasmids and viruses Quantitative Reverse Transcription PCR Generation of molecular standard for quantitative PCR

Supplemental Materials and Methods Plasmids and viruses Quantitative Reverse Transcription PCR Generation of molecular standard for quantitative PCR Supplemental Materials and Methods Plasmids and viruses To generate pseudotyped viruses, the previously described recombinant plasmids pnl4-3-δnef-gfp or pnl4-3-δ6-drgfp and a vector expressing HIV-1 X4

More information

Retroviruses. ---The name retrovirus comes from the enzyme, reverse transcriptase.

Retroviruses. ---The name retrovirus comes from the enzyme, reverse transcriptase. Retroviruses ---The name retrovirus comes from the enzyme, reverse transcriptase. ---Reverse transcriptase (RT) converts the RNA genome present in the virus particle into DNA. ---RT discovered in 1970.

More information

Human Immunodeficiency Virus

Human Immunodeficiency Virus Human Immunodeficiency Virus Virion Genome Genes and proteins Viruses and hosts Diseases Distinctive characteristics Viruses and hosts Lentivirus from Latin lentis (slow), for slow progression of disease

More information

Figure S1. Schematic presentation of genomic replication of idsiv after transfection and infection. After transfection of idsiv plasmid DNA into 293T

Figure S1. Schematic presentation of genomic replication of idsiv after transfection and infection. After transfection of idsiv plasmid DNA into 293T Figure S1. Schematic presentation of genomic replication of idsiv after transfection and infection. After transfection of idsiv plasmid DNA into 293T cells, the RNA genomes with all modifications are generated

More information

Fayth K. Yoshimura, Ph.D. September 7, of 7 RETROVIRUSES. 2. HTLV-II causes hairy T-cell leukemia

Fayth K. Yoshimura, Ph.D. September 7, of 7 RETROVIRUSES. 2. HTLV-II causes hairy T-cell leukemia 1 of 7 I. Diseases Caused by Retroviruses RETROVIRUSES A. Human retroviruses that cause cancers 1. HTLV-I causes adult T-cell leukemia and tropical spastic paraparesis 2. HTLV-II causes hairy T-cell leukemia

More information

Viral Vectors In The Research Laboratory: Just How Safe Are They? Dawn P. Wooley, Ph.D., SM(NRM), RBP, CBSP

Viral Vectors In The Research Laboratory: Just How Safe Are They? Dawn P. Wooley, Ph.D., SM(NRM), RBP, CBSP Viral Vectors In The Research Laboratory: Just How Safe Are They? Dawn P. Wooley, Ph.D., SM(NRM), RBP, CBSP 1 Learning Objectives Recognize hazards associated with viral vectors in research and animal

More information

Supplementary information. MARCH8 inhibits HIV-1 infection by reducing virion incorporation of envelope glycoproteins

Supplementary information. MARCH8 inhibits HIV-1 infection by reducing virion incorporation of envelope glycoproteins Supplementary information inhibits HIV-1 infection by reducing virion incorporation of envelope glycoproteins Takuya Tada, Yanzhao Zhang, Takayoshi Koyama, Minoru Tobiume, Yasuko Tsunetsugu-Yokota, Shoji

More information

~Lentivirus production~

~Lentivirus production~ ~Lentivirus production~ May 30, 2008 RNAi core R&D group member Lentivirus Production Session Lentivirus!!! Is it health threatening to lab technician? What s so good about this RNAi library? How to produce

More information

Immunization with single-cycle SIV significantly reduces viral loads after an intravenous challenge with SIV(mac)239

Immunization with single-cycle SIV significantly reduces viral loads after an intravenous challenge with SIV(mac)239 University of Massachusetts Medical School escholarship@umms Preventive and Behavioral Medicine Publications and Presentations Preventive and Behavioral Medicine 1-23-2009 Immunization with single-cycle

More information

CURRENT DEVELOMENTS AND FUTURE PROSPECTS FOR HIV GENE THERAPY USING INTERFERING RNA-BASED STRATEGIES

CURRENT DEVELOMENTS AND FUTURE PROSPECTS FOR HIV GENE THERAPY USING INTERFERING RNA-BASED STRATEGIES [Frontiers in Bioscience 5, d527-555, May 1, 2000] CURRENT DEVELOMENTS AND FUTURE PROSPECTS FOR HIV GENE THERAPY USING INTERFERING RNA-BASED STRATEGIES Betty Lamothe, Sadhna Joshi Department of Medical

More information

Immunization with Single-Cycle SIV Significantly Reduces Viral Loads After an Intravenous Challenge with SIV mac 239

Immunization with Single-Cycle SIV Significantly Reduces Viral Loads After an Intravenous Challenge with SIV mac 239 Immunization with Single-Cycle SIV Significantly Reduces Viral Loads After an Intravenous Challenge with SIV mac 239 Bin Jia 1, Sharon K. Ng 1, M. Quinn DeGottardi 1, Michael Piatak Jr. 2, Eloísa Yuste

More information

Clinical Significance of Human Immunodeficiency Virus Type 1 Replication Fitness

Clinical Significance of Human Immunodeficiency Virus Type 1 Replication Fitness CLINICAL MICROBIOLOGY REVIEWS, Oct. 2007, p. 550 578 Vol. 20, No. 4 0893-8512/07/$08.00 0 doi:10.1128/cmr.00017-07 Copyright 2007, American Society for Microbiology. All Rights Reserved. Clinical Significance

More information

HIV-1 p24 ELISA Pair Set Cat#: orb54951 (ELISA Manual)

HIV-1 p24 ELISA Pair Set Cat#: orb54951 (ELISA Manual) HIV-1 p24 ELISA Pair Set Cat#: orb54951 (ELISA Manual) BACKGROUND Human Immunodeficiency Virus ( HIV ) can be divided into two major types, HIV type 1 (HIV-1) and HIV type 2 (HIV-2). HIV-1 is related to

More information

HIV INFECTION: An Overview

HIV INFECTION: An Overview HIV INFECTION: An Overview UNIVERSITY OF PAPUA NEW GUINEA SCHOOL OF MEDICINE AND HEALTH SCIENCES DIVISION OF BASIC MEDICAL SCIENCES DISCIPLINE OF BIOCHEMISTRY & MOLECULAR BIOLOGY PBL MBBS II SEMINAR VJ

More information

Under the Radar Screen: How Bugs Trick Our Immune Defenses

Under the Radar Screen: How Bugs Trick Our Immune Defenses Under the Radar Screen: How Bugs Trick Our Immune Defenses Session 7: Cytokines Marie-Eve Paquet and Gijsbert Grotenbreg Whitehead Institute for Biomedical Research HHV-8 Discovered in the 1980 s at the

More information

Micropathology Ltd. University of Warwick Science Park, Venture Centre, Sir William Lyons Road, Coventry CV4 7EZ

Micropathology Ltd. University of Warwick Science Park, Venture Centre, Sir William Lyons Road, Coventry CV4 7EZ www.micropathology.com info@micropathology.com Micropathology Ltd Tel 24hrs: +44 (0) 24-76 323222 Fax / Ans: +44 (0) 24-76 - 323333 University of Warwick Science Park, Venture Centre, Sir William Lyons

More information

Human Immunodeficiency Virus type 1 (HIV-1) p24 / Capsid Protein p24 ELISA Pair Set

Human Immunodeficiency Virus type 1 (HIV-1) p24 / Capsid Protein p24 ELISA Pair Set Human Immunodeficiency Virus type 1 (HIV-1) p24 / Capsid Protein p24 ELISA Pair Set Catalog Number : SEK11695 To achieve the best assay results, this manual must be read carefully before using this product

More information

HIV-1 Virus-like Particle Budding Assay Nathan H Vande Burgt, Luis J Cocka * and Paul Bates

HIV-1 Virus-like Particle Budding Assay Nathan H Vande Burgt, Luis J Cocka * and Paul Bates HIV-1 Virus-like Particle Budding Assay Nathan H Vande Burgt, Luis J Cocka * and Paul Bates Department of Microbiology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, USA

More information

MedChem 401~ Retroviridae. Retroviridae

MedChem 401~ Retroviridae. Retroviridae MedChem 401~ Retroviridae Retroviruses plus-sense RNA genome (!8-10 kb) protein capsid lipid envelop envelope glycoproteins reverse transcriptase enzyme integrase enzyme protease enzyme Retroviridae The

More information

HIV 101: Fundamentals of HIV Infection

HIV 101: Fundamentals of HIV Infection HIV 101: Fundamentals of HIV Infection David H. Spach, MD Professor of Medicine University of Washington Seattle, Washington Learning Objectives After attending this presentation, learners will be able

More information

numbe r Done by Corrected by Doctor

numbe r Done by Corrected by Doctor numbe r 5 Done by Mustafa Khader Corrected by Mahdi Sharawi Doctor Ashraf Khasawneh Viral Replication Mechanisms: (Protein Synthesis) 1. Monocistronic Method: All human cells practice the monocistronic

More information

HIV & AIDS: Overview

HIV & AIDS: Overview HIV & AIDS: Overview UNIVERSITY OF PAPUA NEW GUINEA SCHOOL OF MEDICINE AND HEALTH SCIENCES DIVISION OF BASIC MEDICAL SCIENCES DISCIPLINE OF BIOCHEMISTRY & MOLECULAR BIOLOGY PBL SEMINAR VJ TEMPLE 1 What

More information

Section 6. Junaid Malek, M.D.

Section 6. Junaid Malek, M.D. Section 6 Junaid Malek, M.D. The Golgi and gp160 gp160 transported from ER to the Golgi in coated vesicles These coated vesicles fuse to the cis portion of the Golgi and deposit their cargo in the cisternae

More information

A VACCINE FOR HIV BIOE 301 LECTURE 10 MITALI BANERJEE HAART

A VACCINE FOR HIV BIOE 301 LECTURE 10 MITALI BANERJEE HAART BIOE 301 LECTURE 10 MITALI BANERJEE A VACCINE FOR HIV HIV HAART Visit wikipedia.org and learn the mechanism of action of the five classes of antiretroviral drugs. (1) Reverse transcriptase inhibitors (RTIs)

More information

Supporting Information

Supporting Information Supporting Information Hatziioannou et al. 10.1073/pnas.0812587106 SI Text Viral Constructs and Viral Stock Generation. To generate the HIV-1 constructs used throughout these studies, the env gene in an

More information

Sarah A. Kopecky and Douglas S. Lyles*

Sarah A. Kopecky and Douglas S. Lyles* JOURNAL OF VIROLOGY, Apr. 2003, p. 4658 4669 Vol. 77, No. 8 0022-538X/03/$08.00 0 DOI: 10.1128/JVI.77.8.4658 4669.2003 Copyright 2003, American Society for Microbiology. All Rights Reserved. Contrasting

More information

Nature Medicine: doi: /nm.2109

Nature Medicine: doi: /nm.2109 HIV 1 Infects Multipotent Progenitor Cells Causing Cell Death and Establishing Latent Cellular Reservoirs Christoph C. Carter, Adewunmi Onafuwa Nuga, Lucy A. M c Namara, James Riddell IV, Dale Bixby, Michael

More information

Hepatitis B Antiviral Drug Development Multi-Marker Screening Assay

Hepatitis B Antiviral Drug Development Multi-Marker Screening Assay Hepatitis B Antiviral Drug Development Multi-Marker Screening Assay Background ImQuest BioSciences has developed and qualified a single-plate method to expedite the screening of antiviral agents against

More information

Islet viability assay and Glucose Stimulated Insulin Secretion assay RT-PCR and Western Blot

Islet viability assay and Glucose Stimulated Insulin Secretion assay RT-PCR and Western Blot Islet viability assay and Glucose Stimulated Insulin Secretion assay Islet cell viability was determined by colorimetric (3-(4,5-dimethylthiazol-2-yl)-2,5- diphenyltetrazolium bromide assay using CellTiter

More information

7.012 Quiz 3 Answers

7.012 Quiz 3 Answers MIT Biology Department 7.012: Introductory Biology - Fall 2004 Instructors: Professor Eric Lander, Professor Robert A. Weinberg, Dr. Claudette Gardel Friday 11/12/04 7.012 Quiz 3 Answers A > 85 B 72-84

More information

Supplementary Information. Supplementary Figure 1

Supplementary Information. Supplementary Figure 1 Supplementary Information Supplementary Figure 1 1 Supplementary Figure 1. Functional assay of the hcas9-2a-mcherry construct (a) Gene correction of a mutant EGFP reporter cell line mediated by hcas9 or

More information

CDC site UNAIDS Aids Knowledge Base http://www.cdc.gov/hiv/dhap.htm http://hivinsite.ucsf.edu/insite.jsp?page=kb National Institute of Allergy and Infectious Diseases http://www.niaid.nih.gov/default.htm

More information

Received 30 January 2002/Accepted 18 December 2002

Received 30 January 2002/Accepted 18 December 2002 JOURNAL OF VIROLOGY, Mar. 2003, p. 3634 3646 Vol. 77, No. 6 0022-538X/03/$08.00 0 DOI: 10.1128/JVI.77.6.3634 3646.2003 Copyright 2003, American Society for Microbiology. All Rights Reserved. Rational Site-Directed

More information

Identification of Mutation(s) in. Associated with Neutralization Resistance. Miah Blomquist

Identification of Mutation(s) in. Associated with Neutralization Resistance. Miah Blomquist Identification of Mutation(s) in the HIV 1 gp41 Subunit Associated with Neutralization Resistance Miah Blomquist What is HIV 1? HIV-1 is an epidemic that affects over 34 million people worldwide. HIV-1

More information

Supplementary Material

Supplementary Material Supplementary Material Nuclear import of purified HIV-1 Integrase. Integrase remains associated to the RTC throughout the infection process until provirus integration occurs and is therefore one likely

More information

JOURNAL OF VIROLOGY, Jan. 1999, p Vol. 73, No. 1. Copyright 1999, American Society for Microbiology. All Rights Reserved.

JOURNAL OF VIROLOGY, Jan. 1999, p Vol. 73, No. 1. Copyright 1999, American Society for Microbiology. All Rights Reserved. JOURNAL OF VIROLOGY, Jan. 1999, p. 19 28 Vol. 73, No. 1 0022-538X/99/$04.00 0 Copyright 1999, American Society for Microbiology. All Rights Reserved. Mutational Analysis of the Hydrophobic Tail of the

More information

Sequences in the 5 and 3 R Elements of Human Immunodeficiency Virus Type 1 Critical for Efficient Reverse Transcription

Sequences in the 5 and 3 R Elements of Human Immunodeficiency Virus Type 1 Critical for Efficient Reverse Transcription JOURNAL OF VIROLOGY, Sept. 2000, p. 8324 8334 Vol. 74, No. 18 0022-538X/00/$04.00 0 Copyright 2000, American Society for Microbiology. All Rights Reserved. Sequences in the 5 and 3 R Elements of Human

More information

Recombinant Protein Expression Retroviral system

Recombinant Protein Expression Retroviral system Recombinant Protein Expression Retroviral system Viruses Contains genome DNA or RNA Genome encased in a protein coat or capsid. Some viruses have membrane covering protein coat enveloped virus Ø Essential

More information

Received 19 May 2004/Accepted 13 September 2004

Received 19 May 2004/Accepted 13 September 2004 JOURNAL OF VIROLOGY, Feb. 2005, p. 1666 1677 Vol. 79, No. 3 0022-538X/05/$08.00 0 doi:10.1128/jvi.79.3.1666 1677.2005 Copyright 2005, American Society for Microbiology. All Rights Reserved. Genetic Recombination

More information

Multi-step inhibition explains HIV-1 protease inhibitor pharmacodynamics and resistance

Multi-step inhibition explains HIV-1 protease inhibitor pharmacodynamics and resistance Research article Related article, page 3704 Multi-step inhibition explains HIV-1 protease inhibitor pharmacodynamics and resistance S. Alireza Rabi, 1 Gregory M. Laird, 1 Christine M. Durand, 1 Sarah Laskey,

More information

X/01/$ DOI: /JVI Copyright 2001, American Society for Microbiology. All Rights Reserved.

X/01/$ DOI: /JVI Copyright 2001, American Society for Microbiology. All Rights Reserved. JOURNAL OF VIROLOGY, Apr. 2001, p. 3753 3765 Vol. 75, No. 8 0022-538X/01/$04.00 0 DOI: 10.1128/JVI.75.8.3753 3765.2001 Copyright 2001, American Society for Microbiology. All Rights Reserved. Route of Simian

More information

Primate and Feline Lentivirus Vector RNA Packaging and Propagation by Heterologous Lentivirus Virions

Primate and Feline Lentivirus Vector RNA Packaging and Propagation by Heterologous Lentivirus Virions JOURNAL OF VIROLOGY, June 2001, p. 5129 5140 Vol. 75, No. 11 0022-538X/01/$04.00 0 DOI: 10.1128/JVI.75.11.5129 5140.2001 Copyright 2001, American Society for Microbiology. All Rights Reserved. Primate

More information

MicroRNA sponges: competitive inhibitors of small RNAs in mammalian cells

MicroRNA sponges: competitive inhibitors of small RNAs in mammalian cells MicroRNA sponges: competitive inhibitors of small RNAs in mammalian cells Margaret S Ebert, Joel R Neilson & Phillip A Sharp Supplementary figures and text: Supplementary Figure 1. Effect of sponges on

More information

Introduction retroposon

Introduction retroposon 17.1 - Introduction A retrovirus is an RNA virus able to convert its sequence into DNA by reverse transcription A retroposon (retrotransposon) is a transposon that mobilizes via an RNA form; the DNA element

More information

LESSON 4.4 WORKBOOK. How viruses make us sick: Viral Replication

LESSON 4.4 WORKBOOK. How viruses make us sick: Viral Replication DEFINITIONS OF TERMS Eukaryotic: Non-bacterial cell type (bacteria are prokaryotes).. LESSON 4.4 WORKBOOK How viruses make us sick: Viral Replication This lesson extends the principles we learned in Unit

More information

Structure of HIV. Virion contains a membrane envelope with a single viral protein= Env protein. Capsid made up of Gag protein

Structure of HIV. Virion contains a membrane envelope with a single viral protein= Env protein. Capsid made up of Gag protein Structure of HIV Virion contains a membrane envelope with a single viral protein= Env protein Important in receptor recognition Capsid made up of Gag protein (group-specific antigen) Icosahedral Interior

More information

HIV/AIDS. Biology of HIV. Research Feature. Related Links. See Also

HIV/AIDS. Biology of HIV. Research Feature. Related Links. See Also 6/1/2011 Biology of HIV Biology of HIV HIV belongs to a class of viruses known as retroviruses. Retroviruses are viruses that contain RNA (ribonucleic acid) as their genetic material. After infecting a

More information

Inhibition of trna 3 Lys -Primed Reverse Transcription by Human APOBEC3G during Human Immunodeficiency Virus Type 1 Replication

Inhibition of trna 3 Lys -Primed Reverse Transcription by Human APOBEC3G during Human Immunodeficiency Virus Type 1 Replication JOURNAL OF VIROLOGY, Dec. 2006, p. 11710 11722 Vol. 80, No. 23 0022-538X/06/$08.00 0 doi:10.1128/jvi.01038-06 Copyright 2006, American Society for Microbiology. All Rights Reserved. Inhibition of trna

More information

HIV Immunopathogenesis. Modeling the Immune System May 2, 2007

HIV Immunopathogenesis. Modeling the Immune System May 2, 2007 HIV Immunopathogenesis Modeling the Immune System May 2, 2007 Question 1 : Explain how HIV infects the host Zafer Iscan Yuanjian Wang Zufferey Abhishek Garg How does HIV infect the host? HIV infection

More information

DATA SHEET. Provided: 500 µl of 5.6 mm Tris HCl, 4.4 mm Tris base, 0.05% sodium azide 0.1 mm EDTA, 5 mg/liter calf thymus DNA.

DATA SHEET. Provided: 500 µl of 5.6 mm Tris HCl, 4.4 mm Tris base, 0.05% sodium azide 0.1 mm EDTA, 5 mg/liter calf thymus DNA. Viral Load DNA >> Standard PCR standard 0 Copies Catalog Number: 1122 Lot Number: 150298 Release Category: A Provided: 500 µl of 5.6 mm Tris HCl, 4.4 mm Tris base, 0.05% sodium azide 0.1 mm EDTA, 5 mg/liter

More information

I m B m. 1 f ub I B. D m B. f u. 1 f ua 1 D I A. I A m. D m A. f a. 1 f u. D m B ) D m A )(I m B. 1 f ua. 1 (I m A. log (I A. log f.

I m B m. 1 f ub I B. D m B. f u. 1 f ua 1 D I A. I A m. D m A. f a. 1 f u. D m B ) D m A )(I m B. 1 f ua. 1 (I m A. log (I A. log f. Supplementary Material Appendix 1 Here we show that independent inhibition by a single drug of two distinct steps (A and ) in the viral life cycle results in a non-linear median effect dose-response curve

More information

number Done by Corrected by Doctor Ashraf

number Done by Corrected by Doctor Ashraf number 4 Done by Nedaa Bani Ata Corrected by Rama Nada Doctor Ashraf Genome replication and gene expression Remember the steps of viral replication from the last lecture: Attachment, Adsorption, Penetration,

More information

ACQUIRED IMMUNODEFICIENCY SYNDROME AND ITS OCULAR COMPLICATIONS

ACQUIRED IMMUNODEFICIENCY SYNDROME AND ITS OCULAR COMPLICATIONS ACQUIRED IMMUNODEFICIENCY SYNDROME AND ITS OCULAR COMPLICATIONS Acquired immunodeficiency syndrome (AIDS ) is an infectious disease caused by a retrovirus, the human immunodeficiency virus(hiv). AIDS is

More information

VIRAL TITER COUNTS. The best methods of measuring infectious lentiviral titer

VIRAL TITER COUNTS. The best methods of measuring infectious lentiviral titer VIRAL TITER COUNTS The best methods of measuring infectious lentiviral titer FLUORESCENCE CYCLES qpcr of Viral RNA SUMMARY Viral vectors are now routinely used for gene transduction in a wide variety of

More information

Julianne Edwards. Retroviruses. Spring 2010

Julianne Edwards. Retroviruses. Spring 2010 Retroviruses Spring 2010 A retrovirus can simply be referred to as an infectious particle which replicates backwards even though there are many different types of retroviruses. More specifically, a retrovirus

More information

Received 8 October 1997/Accepted 5 January 1998

Received 8 October 1997/Accepted 5 January 1998 JOURNAL OF VIROLOGY, Apr. 1998, p. 3248 3258 Vol. 72, No. 4 0022-538X/98/$04.00 0 Copyright 1998, American Society for Microbiology In Vivo Replication Capacity Rather Than In Vitro Macrophage Tropism

More information

Supplementary data Supplementary Figure 1 Supplementary Figure 2

Supplementary data Supplementary Figure 1 Supplementary Figure 2 Supplementary data Supplementary Figure 1 SPHK1 sirna increases RANKL-induced osteoclastogenesis in RAW264.7 cell culture. (A) RAW264.7 cells were transfected with oligocassettes containing SPHK1 sirna

More information

SUPPLEMENTARY INFORMATION

SUPPLEMENTARY INFORMATION sirna pool: Control Tetherin -HA-GFP HA-Tetherin -Tubulin Supplementary Figure S1. Knockdown of HA-tagged tetherin expression by tetherin specific sirnas. HeLa cells were cotransfected with plasmids expressing

More information

Development of a replication-competent lentivirus assay for dendritic cell-targeting lentiviral vectors

Development of a replication-competent lentivirus assay for dendritic cell-targeting lentiviral vectors Citation: Molecular Therapy Methods & Clinical Development (2015) 2, 15017; doi:10.1038/mtm.2015.17 All rights reserved 2329-0501/15 www.nature.com/mtm Article Development of a replication-competent lentivirus

More information

HEK293FT cells were transiently transfected with reporters, N3-ICD construct and

HEK293FT cells were transiently transfected with reporters, N3-ICD construct and Supplementary Information Luciferase reporter assay HEK293FT cells were transiently transfected with reporters, N3-ICD construct and increased amounts of wild type or kinase inactive EGFR. Transfections

More information

GOVX-B11: A Clade B HIV Vaccine for the Developed World

GOVX-B11: A Clade B HIV Vaccine for the Developed World GeoVax Labs, Inc. 19 Lake Park Drive Suite 3 Atlanta, GA 3 (678) 384-72 GOVX-B11: A Clade B HIV Vaccine for the Developed World Executive summary: GOVX-B11 is a Clade B HIV vaccine targeted for use in

More information

Fig. 1: Schematic diagram of basic structure of HIV

Fig. 1: Schematic diagram of basic structure of HIV UNIVERSITY OF PAPUA NEW GUINEA SCHOOL OF MEDICINE AND HEALTH SCIENCES DIVISION OF BASIC MEDICAL SCIENCES DISCIPLINE OF BIOCHEMISTRY & MOLECULAR BIOLOGY PBL SEMINAR HIV & AIDS: An Overview What is HIV?

More information

Running Head: AN UNDERSTANDING OF HIV- 1, SYMPTOMS, AND TREATMENTS. An Understanding of HIV- 1, Symptoms, and Treatments.

Running Head: AN UNDERSTANDING OF HIV- 1, SYMPTOMS, AND TREATMENTS. An Understanding of HIV- 1, Symptoms, and Treatments. Running Head: AN UNDERSTANDING OF HIV- 1, SYMPTOMS, AND TREATMENTS An Understanding of HIV- 1, Symptoms, and Treatments Benjamin Mills Abstract HIV- 1 is a virus that has had major impacts worldwide. Numerous

More information

Qin Yu and Casey D. Morrow 1. Department of Microbiology, University of Alabama at Birmingham, Birmingham, Alabama 35294

Qin Yu and Casey D. Morrow 1. Department of Microbiology, University of Alabama at Birmingham, Birmingham, Alabama 35294 Virology 254, 160 168 (1999) Article ID viro.1998.9542, available online at http://www.idealibrary.com on Complementarity between 3 Terminal Nucleotides of trna and Primer Binding Site Is a Major Determinant

More information

Current Strategies in HIV-1 Vaccine Development Using Replication-Defective Adenovirus as a Case Study

Current Strategies in HIV-1 Vaccine Development Using Replication-Defective Adenovirus as a Case Study Note: I have added some clarifying comments to the slides -- please click on Comments under View to see them. Current Strategies in HIV-1 Vaccine Development Using Replication-Defective Adenovirus as a

More information

Supplementary Figure 1. SC35M polymerase activity in the presence of Bat or SC35M NP encoded from the phw2000 rescue plasmid.

Supplementary Figure 1. SC35M polymerase activity in the presence of Bat or SC35M NP encoded from the phw2000 rescue plasmid. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 Supplementary Figure 1. SC35M polymerase activity in the presence of Bat or SC35M NP encoded from the phw2000 rescue plasmid. HEK293T

More information

A Single Polymorphism in HIV-1 Subtype C SP1 Is Sufficient To Confer Natural Resistance to the Maturation Inhibitor Bevirimat

A Single Polymorphism in HIV-1 Subtype C SP1 Is Sufficient To Confer Natural Resistance to the Maturation Inhibitor Bevirimat ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, July 2011, p. 3324 3329 Vol. 55, No. 7 0066-4804/11/$12.00 doi:10.1128/aac.01435-10 Copyright 2011, American Society for Microbiology. All Rights Reserved. A Single

More information

Role of the C terminus Gag protein in human immunodefieieney virus type 1 virion assembly and maturation

Role of the C terminus Gag protein in human immunodefieieney virus type 1 virion assembly and maturation Journal of General Virology (1995), 76, 3171-3179. Printed in Great Britain 3171 Role of the C terminus Gag protein in human immunodefieieney virus type 1 virion assembly and maturation X.-F. Yu, ~ Z.

More information

Mark Pandori,* Heather Craig, Laure Moutouh, Jacques Corbeil, and John Guatelli*,,1

Mark Pandori,* Heather Craig, Laure Moutouh, Jacques Corbeil, and John Guatelli*,,1 VIROLOGY 251, 302 316 (1998) ARTICLE NO. VY989407 Virological Importance of the Protease-Cleavage Site in Human Immunodeficiency Virus Type 1 Nef Is Independent of both Intravirion Processing and CD4 Down-regulation

More information

Polyomaviridae. Spring

Polyomaviridae. Spring Polyomaviridae Spring 2002 331 Antibody Prevalence for BK & JC Viruses Spring 2002 332 Polyoma Viruses General characteristics Papovaviridae: PA - papilloma; PO - polyoma; VA - vacuolating agent a. 45nm

More information

CHAPTER 4 RESULTS. showed that all three replicates had similar growth trends (Figure 4.1) (p<0.05; p=0.0000)

CHAPTER 4 RESULTS. showed that all three replicates had similar growth trends (Figure 4.1) (p<0.05; p=0.0000) CHAPTER 4 RESULTS 4.1 Growth Characterization of C. vulgaris 4.1.1 Optical Density Growth study of Chlorella vulgaris based on optical density at 620 nm (OD 620 ) showed that all three replicates had similar

More information

Chapter 13 Viruses, Viroids, and Prions. Biology 1009 Microbiology Johnson-Summer 2003

Chapter 13 Viruses, Viroids, and Prions. Biology 1009 Microbiology Johnson-Summer 2003 Chapter 13 Viruses, Viroids, and Prions Biology 1009 Microbiology Johnson-Summer 2003 Viruses Virology-study of viruses Characteristics: acellular obligate intracellular parasites no ribosomes or means

More information

CRISPRaTest Functional dcas9-activator Assay Kit v1 Last update: 2018/07/04 Cellecta, Inc.

CRISPRaTest Functional dcas9-activator Assay Kit v1 Last update: 2018/07/04 Cellecta, Inc. CRISPRaTest Functional dcas9-activator Assay Kit v1 Last update: 2018/07/04 Cellecta, Inc. Copyright (c) 2018 Cellecta, Inc. All Rights Reserved. Table of Contents 1. CRISPRaTest Functional dcas9-activator

More information

Received 3 September 2002/Accepted 15 January 2003

Received 3 September 2002/Accepted 15 January 2003 JOURNAL OF VIROLOGY, Apr. 2003, p. 4646 4657 Vol. 77, No. 8 0022-538X/03/$08.00 0 DOI: 10.1128/JVI.77.8.4646 4657.2003 Copyright 2003, American Society for Microbiology. All Rights Reserved. Ability of

More information

ARV Mode of Action. Mode of Action. Mode of Action NRTI. Immunopaedia.org.za

ARV Mode of Action. Mode of Action. Mode of Action NRTI. Immunopaedia.org.za ARV Mode of Action Mode of Action Mode of Action - NRTI Mode of Action - NNRTI Mode of Action - Protease Inhibitors Mode of Action - Integrase inhibitor Mode of Action - Entry Inhibitors Mode of Action

More information

Jumpstart your research with ViraPower Lentiviral Expression Systems

Jumpstart your research with ViraPower Lentiviral Expression Systems ViraPower Lentiviral Expression Systems Jumpstart your research with ViraPower Lentiviral Expression Systems With ViraPower Lentiviral Systems you can: Efficiently transduce both dividing and non-dividing

More information

Certificate of Analysis

Certificate of Analysis Certificate of Analysis Catalog No. Amount Lot Number 631987 10 μg Specified on product label. Product Information plvx-ef1α-ires-mcherry is a bicistronic lentiviral expression vector that can be used

More information

Centers for Disease Control August 9, 2004

Centers for Disease Control August 9, 2004 HIV CDC site UNAIDS Aids Knowledge Base http://www.cdc.gov/hiv/dhap.htm http://hivinsite.ucsf.edu/insite.jsp?page=kb National Institute of Allergy and Infectious Diseases http://www.niaid.nih.gov/default.htm

More information

Online Data Supplement. Anti-aging Gene Klotho Enhances Glucose-induced Insulin Secretion by Upregulating Plasma Membrane Retention of TRPV2

Online Data Supplement. Anti-aging Gene Klotho Enhances Glucose-induced Insulin Secretion by Upregulating Plasma Membrane Retention of TRPV2 Online Data Supplement Anti-aging Gene Klotho Enhances Glucose-induced Insulin Secretion by Upregulating Plasma Membrane Retention of TRPV2 Yi Lin and Zhongjie Sun Department of physiology, college of

More information

HUMAN IMMUNODEFICIENCY VIRUS

HUMAN IMMUNODEFICIENCY VIRUS Futuro promisorio de la terapia antirretroviral: Nuevos blancos terapéuticos. María José Míguez, M.D., PhD., Universidad de Miami, EE.UU. HUMAN IMMUNODEFICIENCY VIRUS REVERSE TRANSCRIPTASA REPLICATION

More information

Lentiviruses: HIV-1 Pathogenesis

Lentiviruses: HIV-1 Pathogenesis Lentiviruses: HIV-1 Pathogenesis Human Immunodeficiency Virus, HIV, computer graphic by Russell Kightley Tsafi Pe ery, Ph.D. Departments of Medicine and Biochemistry & Molecular Biology NJMS, UMDNJ. e-mail:

More information

human immunodeficiency virus, type 1; PI, protease inhibitor; LPV, lopinavir;

human immunodeficiency virus, type 1; PI, protease inhibitor; LPV, lopinavir; THE JOURNAL OF BIOLOGICAL CHEMISTRY VOL. 284, NO. 43, pp. 29692 29703, October 23, 2009 2009 by The American Society for Biochemistry and Molecular Biology, Inc. Printed in the U.S.A. HIV-1 Gag Processing

More information

on August 19, 2018 by guest

on August 19, 2018 by guest JOURNAL OF VIROLOGY, Nov. 1999, p. 9589 9598 Vol. 73, No. 11 0022-538X/99/$04.00 0 Copyright 1999, American Society for Microbiology. All Rights Reserved. A Lentivirus Packaging System Based on Alternative

More information

HIV-1 p24 Antigen ELISA 2.0 Catalog Number:

HIV-1 p24 Antigen ELISA 2.0 Catalog Number: INTENDED USE The RETRO-TEK HIV-1 p24 Antigen ELISA 2.0 is an enzyme linked immunoassay used to detect Human Immunodeficiency Virus Type 1 (HIV-1) p24 antigen in cell culture media. It can be used to monitor

More information

Viral Genetics. BIT 220 Chapter 16

Viral Genetics. BIT 220 Chapter 16 Viral Genetics BIT 220 Chapter 16 Details of the Virus Classified According to a. DNA or RNA b. Enveloped or Non-Enveloped c. Single-stranded or double-stranded Viruses contain only a few genes Reverse

More information

QuickTiter Lentivirus Titer Kit (Lentivirus-Associated HIV p24)

QuickTiter Lentivirus Titer Kit (Lentivirus-Associated HIV p24) Product Manual QuickTiter Lentivirus Titer Kit (Lentivirus-Associated HIV p24) Catalog Number VPK-107 VPK-107-5 96 assays 5 x 96 assays FOR RESEARCH USE ONLY Not for use in diagnostic procedures Introduction

More information

, virus identified as the causative agent and ELISA test produced which showed the extent of the epidemic

, virus identified as the causative agent and ELISA test produced which showed the extent of the epidemic 1 Two attributes make AIDS unique among infectious diseases: it is uniformly fatal, and most of its devastating symptoms are not due to the causative agent Male to Male sex is the highest risk group in

More information

Received 29 August 2002/Accepted 3 December 2002

Received 29 August 2002/Accepted 3 December 2002 JOURNAL OF VIROLOGY, Mar. 2003, p. 3099 3118 Vol. 77, No. 5 0022-538X/03/$08.00 0 DOI: 10.1128/JVI.77.5.3099 3118.2003 Copyright 2003, American Society for Microbiology. All Rights Reserved. Simian-Human

More information

JOURNAL OF VIROLOGY, Dec. 2000, p Vol. 74, No. 24. Copyright 2000, American Society for Microbiology. All Rights Reserved.

JOURNAL OF VIROLOGY, Dec. 2000, p Vol. 74, No. 24. Copyright 2000, American Society for Microbiology. All Rights Reserved. JOURNAL OF VIROLOGY, Dec. 2000, p. 11935 11949 Vol. 74, No. 24 0022-538X/00/$04.00 0 Copyright 2000, American Society for Microbiology. All Rights Reserved. Protection of Macaca nemestrina from Disease

More information

Feb 11, Gene Therapy. Sam K.P. Kung Immunology Rm 417 Apotex Center

Feb 11, Gene Therapy. Sam K.P. Kung Immunology Rm 417 Apotex Center Gene Therapy Sam K.P. Kung Immunology Rm 417 Apotex Center Objectives: The concept of gene therapy, and an introduction of some of the currently used gene therapy vector Undesirable immune responses to

More information

Human Immunodeficiency Virus type 1 (HIV-1) gp120 / Glycoprotein 120 ELISA Pair Set

Human Immunodeficiency Virus type 1 (HIV-1) gp120 / Glycoprotein 120 ELISA Pair Set Human Immunodeficiency Virus type 1 (HIV-1) gp120 / Glycoprotein 120 ELISA Pair Set Catalog Number : SEK11233 To achieve the best assay results, this manual must be read carefully before using this product

More information

INI1/hSNF5-interaction defective HIV-1 IN mutants exhibit impaired particle morphology, reverse transcription and integration in vivo

INI1/hSNF5-interaction defective HIV-1 IN mutants exhibit impaired particle morphology, reverse transcription and integration in vivo Mathew et al. Retrovirology 213, 1:66 RESEARCH Open Access INI1/hSNF5-interaction defective HIV-1 IN mutants exhibit impaired particle morphology, reverse transcription and integration in vivo Sheeba Mathew

More information

L I F E S C I E N C E S

L I F E S C I E N C E S 1a L I F E S C I E N C E S 5 -UUA AUA UUC GAA AGC UGC AUC GAA AAC UGU GAA UCA-3 5 -TTA ATA TTC GAA AGC TGC ATC GAA AAC TGT GAA TCA-3 3 -AAT TAT AAG CTT TCG ACG TAG CTT TTG ACA CTT AGT-5 OCTOBER 31, 2006

More information

Helper virus-free transfer of human immunodeficiency virus type 1 vectors

Helper virus-free transfer of human immunodeficiency virus type 1 vectors Journal of General Virology (1995), 76, 691 696. Printed in Great Britabz 691 Helper virus-free transfer of human immunodeficiency virus type 1 vectors Jennifer H. Riehardson,~ Jane F. Kaye, Lisa A. Child

More information

Murine Cytomegalovirus with a Transposon Insertional Mutation at Open Reading Frame M35 Is Defective in Growth In Vivo

Murine Cytomegalovirus with a Transposon Insertional Mutation at Open Reading Frame M35 Is Defective in Growth In Vivo JOURNAL OF VIROLOGY, July 2003, p. 7746 7755 Vol. 77, No. 14 0022-538X/03/$08.00 0 DOI: 10.1128/JVI.77.14.7746 7755.2003 Copyright 2003, American Society for Microbiology. All Rights Reserved. Murine Cytomegalovirus

More information

HIV Diagnostic Testing

HIV Diagnostic Testing In The name of God HIV Diagnostic Testing By : Dr. Shahzamani PhD of Medical virology Purpose of HIV Testing To identify asymptomatic individuals To diagnose HIV infection in those who practice high risk

More information

Human Immunodeficiency Virus Type 1 cdnas Produced in the Presence of APOBEC3G Exhibit Defects in Plus-Strand DNA Transfer and Integration

Human Immunodeficiency Virus Type 1 cdnas Produced in the Presence of APOBEC3G Exhibit Defects in Plus-Strand DNA Transfer and Integration JOURNAL OF VIROLOGY, July 2007, p. 7099 7110 Vol. 81, No. 13 0022-538X/07/$08.00 0 doi:10.1128/jvi.00272-07 Copyright 2007, American Society for Microbiology. All Rights Reserved. Human Immunodeficiency

More information